Navigation Links
Once-Promising Heart Failure Drug Fails in Trial
Date:10/7/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Oct. 6 (HealthDay News) -- A new experimental drug for treating patients who have acute heart failure plus kidney failure did not show any overall benefit, indicating that the future of this particular drug, called rolofylline, is over.

"I think this is the end of the story for this drug," said Dr. Barry Massie, lead author of a study appearing in the Oct. 7 issue of the New England Journal of Medicine. "There was a very promising pilot trial but these results . . . were neutral. I am disappointed," he said.

The results were presented last year at the European Society of Cardiology meeting. Shortly before that, drug company Merck, which has been developing the medicine and which funded this study, announced that it would not be filing for U.S. Food and Drug Administration approval for rolofylline.

Rolofylline is known as an A1-receptor antagonist and is intended to make diuretics work more effectively.

Other drugs in the same class of medications that were developed by other companies have met with similarly disappointing results after promising early results, said Massie, who is chief of the cardiology division at the San Francisco VA Medical Center and professor of medicine at the University of California, San Francisco.

He explained that kidney problems are a major complication of heart failure and "those patients who develop renal [kidney] failure in the course of treatment have a much higher hospital admission and death rate."

This may be at least partly because patients are taken off of certain cardiac medications in order to improve kidney function.

"This is sort of a perfect storm," Massie said.

For this study, just over 2,000 patients who had been hospitalized for acute heart failure and kidney problems were randomly assigned to receive a placebo or 30 milligrams of rolofylline daily intravenously. Treatment lasted for up to three days.

Rolofylline did not prolong survival or improve heart failure or kidney function when compared with the placebo.

And in contrast to the placebo group, some patients taking rolofylline had seizures, indicating that the drug was able to cross the blood-brain barrier. Seizures are a potential side effect for this class of drugs.

"[We] had hoped that the drug didn't cross the blood-brain barrier," Massie said.

One expert was similarly disappointed with the study results.

"Rolofylline certainly does not seem to have benefit in terms of risk of mortality (or death) and hospital readmission," noted Dr. Tara Narula, a cardiologist with Lenox Hill Hospital in New York City. "At this point, unfortunately, we're left with what we have in our arsenal, which we've [already] had for many years."

That includes IV loop diuretics, ACE inhibitors and beta blockers, she said.

More information

There's more on heart failure at the American Heart Association.

SOURCES: Barry M. Massie, M.D., chief, cardiology division, San Francisco VA Medical Center and professor of medicine, University of California, San Francisco; Tara Narula, M.D., cardiologist, Lenox Hill Hospital, New York City; Oct. 7, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Workplace Noise Tied to Heart Disease Risk
2. Testosterone Could Boost Health of Heart Failure Patients
3. Dental Care Linked to Heart Health in Older Women
4. Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment
5. Women who get dental care have lower risk of heart disease, says study
6. WUSTL awarded $18 million to treat heart, lungs with nanotechnology
7. Researchers use CT to predict heart disease
8. ESC announces new initiatives for workplace heart health programs
9. Disparities in heart attack treatment may begin in the emergency room
10. Molecular playbook for halting heart failure risk factor uncovered
11. Surgery May Be Best for Irregular Heartbeat in Young
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Once-Promising Heart Failure Drug Fails in Trial
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: